Pashtoon M. Kasi, MD, MS, University of Iowa, Iowa City, IA, explains that EGFR rechallenge may not be effective in metastatic RAS/RAF wild-type refractory colorectal cancer patients that have acquired mechanisms of resistance to anti-EGFR therapy. He describes a case series, presented at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium 2021, that suggests that circulating tumor DNA (ctDNA)-based testing via liquid biopsy could help to identify patients resistant to EGFR therapy and will not benefit from rechallenge. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

свернуть